Crisaborole 2% topical ointment is a novel, boron-based, nonsteroidal inhibitor of phosphodiesterase 4 (PDE-4). AD is marked by overactivity of PDE-4, which results in decreased levels of cyclic AMP and resultant increased release of inflammatory cytokines.
In my biopsy which was taken by one of the professors showed elevated levels of inflammatory cytokines. so in theory this ointment has the potential to clear my symptoms and control the inflammation.
this ointment is in fda application with a decision due by i think january 6th.